Article Text

Extended report
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study
  1. Bernard Combe1,
  2. Bhaskar Dasgupta2,
  3. Ingrid Louw3,
  4. Sarvajeet Pal4,
  5. Jürgen Wollenhaupt5,
  6. Cristiano A F Zerbini6,
  7. Andre D Beaulieu7,
  8. Hendrik Schulze-Koops8,
  9. Patrick Durez9,
  10. Ruji Yao10,
  11. Nathan Vastesaeger11,
  12. Haoling H Weng10,
  13. on Behalf of the GO-MORE Investigators
  1. 1Hôpital Lapeyronie, Hôpital Lapeyronie, Université Montpellier I, Montpellier, France
  2. 2Southend University Hospital, Westcliff-on-Sea, UK
  3. 3Panorama Medical Centre, Cape Town, South Africa
  4. 4Advance Rheumatology Clinic, Hyderabad, India
  5. 5Schön Klinik Hamburg-Eilbek, Hamburg, Germany
  6. 6Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil
  7. 7Centre de Rhumatologie, St-Louis, Québec, Canada
  8. 8Rheumaeinheit, Med. Klinik and Poliklinik IV, University of Munich, Munich, Germany
  9. 9Service et Pôle de Rhumatologie, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium
  10. 10Merck Sharp and Dohme, Kenilworth, New Jersey, USA
  11. 11Merck Sharp and Dohme, Brussels, Belgium
  1. Correspondence to Professor Bernard Combe, Departement de Rhumatologie, Hôpital Lapeyronie, Université Montpellier I, Montpellier UMR 5535, France; b-combe{at}


Objectives To evaluate the efficacy and safety of subcutaneous golimumab as add-on therapy in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) treatment. To evaluate an intravenous plus subcutaneous (IV+SC) golimumab strategy in patients who had not attained remission.

Methods GO-MORE was an open-label, multinational, prospective study in patients with active RA in typical clinical practice settings. In part 1, patients received add-on monthly 50-mg subcutaneous golimumab for 6 months. The percentage of patients with good/moderate European League Against Rheumatism (EULAR) 28-joint disease activity score (DAS28)–erythrocyte sedimentation rate (ESR) response was compared in patient subgroups with various concurrent or previous DMARD treatments. In part 2, patients with EULAR responses but not remission were randomly assigned to receive IV+SC or subcutaneous golimumab to month 12; DAS28–ESR remission was measured.

Results 3366 patients were enrolled. At baseline of part 1, 3280 efficacy-evaluable patients had mean disease duration of 7.6 years and mean DAS28–ESR of 5.97 (SD=1.095). At month 6, 82.1% achieved good/moderate EULAR responses and 23.9% attained remission. When EULAR responses were analysed by the number of previously failed DMARD or the concomitant methotrexate dose, DMARD type, or corticosteroid use, no statistically significant differences were observed. Part 2 patients (N=490) who received IV+SC or subcutaneous golimumab achieved similar remission rates (∼25%). Adverse events were consistent with previous reports of golimumab and other tumour necrosis antagonists in this population.

Conclusions Add-on monthly subcutaneous golimumab resulted in good/moderate EULAR response in most patients; 25% achieved remission after 6 more months of golimumab, but an IV+SC regimen provided no additional efficacy over the subcutaneous regimen.

  • Rheumatoid Arthritis
  • Methotrexate
  • DMARDs (biologic)

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.